Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma

被引:266
作者
Carey, Christopher D. [1 ,2 ]
Gusenleitner, Daniel [3 ]
Lipschitz, Mikel [3 ]
Roemer, Margaretha G. M. [4 ,5 ]
Stack, Edward C. [6 ]
Gjini, Evisa [3 ]
Hu, Xihao [7 ]
Redd, Robert [7 ]
Freeman, Gordon J. [3 ,4 ]
Neuberg, Donna [7 ]
Hodi, F. Stephen [3 ,4 ]
Liu, Xiaole Shirley [7 ]
Shipp, Margaret A. [3 ,4 ]
Rodig, Scott J. [1 ,3 ]
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA
[2] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
[3] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02115 USA
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands
[6] PerkinElmer Inc, Hopkinton, MA USA
[7] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
基金
美国国家卫生研究院; 英国医学研究理事会;
关键词
BRENTUXIMAB VEDOTIN; SUPPRESSOR-CELLS; T-CELLS; CLASS-I; PD-1; EXPRESSION; PEMBROLIZUMAB; AMPLIFICATION; ANTIBODIES; MOLECULES;
D O I
10.1182/blood-2017-03-770719
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Signaling between programmed cell death protein 1 (PD-1) and the PD-1 ligands (PD-L1, PD-L2) is essential for malignant Hodgkin Reed-Sternberg (HRS) cells to evade antitumor immunity in classical Hodgkin lymphoma (cHL). Copy number alterations of 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) contribute to robust PD-L1 and PD-L2 expression by HRS cells. PD-L1 is also expressed by nonmalignant tumor-associated macrophages (TAMs), but the relationships among PD-L1(+) HRS cells, PD-L1(+) TAMs, and PD-1(+) T cells remain undefined. We used multiplex immunofluorescence and digital image analysis to examine the topography of PD-L1(+) and PD-1(+) cells in the tumor microenvironment (TME) of cHL. We find that the majority of PD-L1 in the TME is expressed by the abundant PD-L1(+) TAMs, which physically colocalize with PD-L1(+) HRS cells in a microenvironmental niche. PD-L1(+) TAMs are enriched for contacts with T cells, and PD-L1(+) HRS cells are enriched for contacts with CD4(+) T cells, a subset of which are PD-1(+). Our data define a unique topology of cHL in which PD-L1(+) TAMs surround HRS cells and implicate CD4(+) T cells as a target of PD-1 blockade.
引用
收藏
页码:2420 / 2430
页数:11
相关论文
共 32 条
[1]   PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[2]   Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure [J].
Armand, Philippe ;
Shipp, Margaret A. ;
Ribrag, Vincent ;
Michot, Jean-Marie ;
Zinzani, Pier Luigi ;
Kuruvilla, John ;
Snyder, Ellen S. ;
Ricart, Alejandro D. ;
Balakumaran, Arun ;
Rose, Shelonitda ;
Moskowitz, Craig H. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) :3733-+
[3]   Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma [J].
Bogusz, Agata M. ;
Baxter, Richard H. G. ;
Currie, Treeve ;
Sinha, Papiya ;
Sohani, Aliyah R. ;
Kutok, Jeffery L. ;
Rodig, Scott J. .
CLINICAL CANCER RESEARCH, 2012, 18 (22) :6122-6135
[4]   PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies [J].
Chen, Benjamin J. ;
Chapuy, Bjoern ;
Jing Ouyang ;
Sun, Heather H. ;
Roemer, Margaretha G. M. ;
Xu, Mina L. ;
Yu, Hongbo ;
Fletcher, Christopher D. M. ;
Freeman, Gordon J. ;
Shipp, Margaret A. ;
Rodig, Scott J. .
CLINICAL CANCER RESEARCH, 2013, 19 (13) :3462-3473
[5]   Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma [J].
Chen, Robert ;
Zinzani, Pier Luigi ;
Fanale, Michelle A. ;
Armand, Philippe ;
Johnson, Nathalie A. ;
Brice, Pauline ;
Radford, John ;
Ribrag, Vincent ;
Molin, Daniel ;
Vassilakopoulos, Theodoros P. ;
Tomita, Akihiro ;
von Tresckow, Bastian ;
Shipp, Margaret A. ;
Zhang, Yinghua ;
Ricart, Alejandro D. ;
Balakumaran, Arun ;
Moskowitz, Craig H. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2125-+
[6]   Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma [J].
Chevolet, I. ;
Speeckaert, R. ;
Schreuer, M. ;
Neyns, B. ;
Krysko, O. ;
Bachert, C. ;
Hennart, B. ;
Allorge, D. ;
van Geel, N. ;
Van Gele, M. ;
Brochez, L. .
ONCOIMMUNOLOGY, 2015, 4 (03) :1-8
[7]   Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma [J].
Diepstra, A ;
Niens, M ;
Vellenga, E ;
van Imhoff, GW ;
Nolte, IM ;
Schaapveld, M ;
van der Steege, G ;
van den Berg, A ;
Kibbelaar, RE ;
te Meerman, GJ ;
Poppema, S .
LANCET, 2005, 365 (9478) :2216-2224
[8]   Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma [J].
Dorfman, DM ;
Brown, JA ;
Shahsafaei, A ;
Freeman, GJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (07) :802-810
[9]   THE MOLECULAR CELL BIOLOGY OF INTERFERON-GAMMA AND ITS RECEPTOR [J].
FARRAR, MA ;
SCHREIBER, RD .
ANNUAL REVIEW OF IMMUNOLOGY, 1993, 11 :571-611
[10]   Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma [J].
Feng, Zipei ;
Puri, Sachin ;
Moudgil, Tarsem ;
Wood, William ;
Hoyt, Clifford C. ;
Wang, Chichung ;
Urba, Walter J. ;
Curti, Brendan D. ;
Bifulco, Carlo B. ;
Fox, Bernard A. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3